Data from a phase 3 study assessing more than 5,000 women and 500 pregnancies support the use of long-acting lenacapavir as HIV pre-exposure prophylaxis among pregnant, postpartum and lactating women, researchers said. Lenacapavir (Yeztugo, Gilead) is administered via two injections given every 6 months. It has been approved for treatment in the United States for people with drug-resistant HIV
Caitlyn Stulpin is a senior staff writer at Healio | Infectious Disease News. She covers a wide range of topics within medicine and healthcare, focusing on issues from antimicrobials to emerging disease outbreaks, and has received multiple APEX awards for her feature writing. Stulpin has been featured in Healio, where her work highlights critical aspects of health and alternative medicine.